Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors

Leukemia

Volumn 31, Issue 1, 2017, Pages 186-194

  Monjezi, R ^a   Miskey, C ^b   Gogishvili, T ^a   Schleef, M ^c   Schmeer, M ^c   Einsele, H ^a   Ivics, Z ^b   Hudecek, M ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b PAUL EHRLICH INSTITUT   (Germany)

^c Dept Process Development   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; KINETOPLAST DNA; LYMPHOCYTE ANTIGEN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ENGINEERING; CELL THERAPY; CONTROLLED STUDY; DNA VECTOR; ELECTROPORATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOMA; MOUSE; MOUSE MODEL; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSPOSON; TUMOR XENOGRAFT; ADOPTIVE IMMUNOTHERAPY; ANIMAL; GENE VECTOR; GENETICS; HEMATOLOGIC NEOPLASMS; IMMUNOLOGY; PROCEDURES; THERAPEUTIC USE; XENOGRAFT;

ANIMALS; ANTIGENS, CD19; CELL ENGINEERING; DNA, KINETOPLAST; GENETIC VECTORS; HEMATOLOGIC NEOPLASMS; HETEROGRAFTS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOMA; MICE; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 84982871882     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.180     Document Type: Article

References (51)

1. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014; 6: 224-225
2. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371: 1507-1517
3. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2015; 33: 540-549
4. Field AC, Vink C, Gabriel R, Al-Subki R, Schmidt M, Goulden N et al. Comparison of lentiviral and sleeping beauty mediated alphabeta T cell receptor gene transfer. PloS One 2013; 8: e68201
5. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-419
6. Wang GP, Levine BL, Binder GK, Berry CC, Malani N, McGarrity G et al. Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells. Mol Ther 2009; 17: 844-850
7. Izsvak Z, Hackett PB, Cooper LJ, Ivics Z. Translating Sleeping Beauty transposition into cellular therapies: victories and challenges. BioEssays 2010; 32: 756-767
8. Swierczek M, Izsvak Z, Ivics Z. The Sleeping Beauty transposon system for clinical applications. Exp Opin Biol Ther 2012; 12: 139-153
9. Ivics Z, Hackett PB, Plasterk RH, Izsvak Z. Molecular reconstruction of sleeping beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell 1997; 91: 501-510
10. Mates L, Chuah MK, Belay E, Jerchow B, Manoj N, Acosta-Sanchez A et al. Molecular evolution of a novel hyperactive sleeping beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet 2009; 41: 753-761
11. Peng PD, Cohen CJ, Yang S, Hsu C, Jones S, Zhao Y et al. Efficient nonviral sleeping beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity. Gene Ther 2009; 16: 1042-1049
12. Huang X, Guo H, Kang J, Choi S, Zhou TC, Tammana S et al. Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies. Mol Ther 2008; 16: 580-589
13. Jin Z, Maiti S, Huls H, Singh H, Olivares S, Mates L et al. The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor. Gene Ther 2011; 18: 849-856
14. Singh H, Manuri PR, Olivares S, Dara N, Dawson MJ, Huls H et al. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res 2008; 68: 2961-2971
15. Singh H, Figliola MJ, Dawson MJ, Olivares S, Zhang L, Yang G et al. Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells. PloS One 2013; 8: e64138
16. Singh H, Huls H, Kebriaei P, Cooper LJ. A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunol Rev 2014; 257: 181-190
17. June CH, Riddell SR, Schumacher TN. Adoptive cellular therapy: a race to the finish line. Sci Transl Med 2015; 7: 280ps287
18. Ramos CA, Savoldo B, Dotti G. CD19-CAR trials. Cancer J 2014; 20: 112-118
19. Mayrhofer P, Schleef M, Jechlinger W. Use of minicircle plasmids for gene therapy. Methods Mol Biol 2009; 542: 87-104
20. Chen ZY, He CY, Ehrhardt A, Kay MA, Minicircle DNA. vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther 2003; 8: 495-500
21. Kay MA, He CY, Chen ZY. A robust system for production of minicircle DNA vectors. Nat Biotechnol 2010; 28: 1287-1289
22. Mayrhofer P, Blaesen M, Schleef M, Jechlinger W. Minicircle-DNA production by site specific recombination and protein-DNA interaction chromatography. J Gene Med 2008; 10: 1253-1269
23. Chabot S, Orio J, Schmeer M, Schleef M, Golzio M, Teissie J, Minicircle DNA. Electrotransfer for efficient tissue-targeted gene delivery. Gene Ther 2013; 20: 62-68
24. Kobelt D, Schleef M, Schmeer M, Aumann J, Schlag PM, Walther W. Performance of high quality minicircle DNA for in vitro and in vivo gene transfer. Mol Biotechnol 2013; 53: 80-89
25. Sharma N, Cai Y, Bak RO, Jakobsen MR, Schroder LD, Mikkelsen JG. Efficient sleeping beauty DNA transposition from DNA minicircles. Mol Ther Nucleic Acids 2013; 2: e74
26. Cui Z, Geurts AM, Liu G, Kaufman CD, Hackett PB. Structure-function analysis of the inverted terminal repeats of the sleeping beauty transposon. J Mol Biol 2002; 318: 1221-1235
27. Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A, Liu L, Rader C et al. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res 2015; 3: 125-135
28. Wang X, Chang WC, Wong CW, Colcher D, Sherman M, Ostberg JR et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 2011; 118: 1255-1263
29. Hudecek M, Lupo-Stanghellini MT, Kosasih PL, Sommermeyer D, Jensen MC, Rader C et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res 2013; 19: 3153-3164
30. Hudecek M, Schmitt TM, Baskar S, Lupo-Stanghellini MT, Nishida T, Yamamoto TN et al. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood 2010; 116: 4532-4541
31. Brown CE, Wright CL, Naranjo A, Vishwanath RP, Chang WC, Olivares S et al. Biophotonic cytotoxicity assay for high-throughput screening of cytolytic killing. J Immunol Methods 2005; 297: 39-52
32. Sommermeyer D, Hudecek M, Kosasih PL, Gogishvili T, Maloney DG, Turtle CJ et al. Chimeric antigen receptor-modified T cells derived from defined CD8 and CD4 subsets confer superior antitumor reactivity in vivo. Leukemia 2015; 30: 492-500
33. Frigault MJ, Lee J, Basil MC, Carpenito C, Motohashi S, Scholler J et al. Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunol Res 2015; 3: 356-367
34. Zayed H, Izsvak Z, Walisko O, Ivics Z. Development of hyperactive sleeping beauty transposon vectors by mutational analysis. Mol Ther 2004; 9: 292-304
35. Vigdal TJ, Kaufman CD, Izsvak Z, Voytas DF, Ivics Z. Common physical properties of DNA affecting target site selection of sleeping beauty and other Tc1/mariner transposable elements. J Mol Biol 2002; 323: 441-452
36. Schones DE, Cui K, Cuddapah S, Roh TY, Barski A, Wang Z et al. Dynamic regulation of nucleosome positioning in the human genome. Cell 2008; 132: 887-898
37. Papapetrou EP, Lee G, Malani N, Setty M, Riviere I, Tirunagari LM et al. Genomic safe harbors permit high beta-globin transgene expression in thalassemia induced pluripotent stem cells. Nat Biotechnol 2011; 29: 73-78
38. Sadelain M, Papapetrou EP, Bushman FD. Safe harbours for the integration of new DNA in the human genome. Nat Revi Cancer 2012; 12: 51-58
39. Papapetrou EP, Schambach A. Gene insertion into genomic safe harbors for human gene therapy. Mol Ther 2016; 24: 678-684
40. Izsvak Z, Ivics Z, Plasterk RH. Sleeping Beauty, a wide host-range transposon vector for genetic transformation in vertebrates. J Mol Biol 2000; 302: 93-102
41. Lukacs GL, Haggie P, Seksek O, Lechardeur D, Freedman N, Verkman AS, Size-dependent DNA. Mobility in cytoplasm and nucleus. J Biol Chem 2000; 275: 1625-1629
42. Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest 2016; 126: 2123-2138
43. Wilber A, Frandsen JL, Geurts JL, Largaespada DA, Hackett PB, McIvor RS. RNA as a source of transposase for Sleeping Beauty-mediated gene insertion and expression in somatic cells and tissues. Mol Ther 2006; 13: 625-630
44. Yant SR, Wu X, Huang Y, Garrison B, Burgess SM, Kay MA. High-resolution genome-wide mapping of transposon integration in mammals. Mol Cell Biol 2005; 25: 2085-2094
45. de Jong J, Akhtar W, Badhai J, Rust AG, Rad R, Hilkens J et al. Chromatin landscapes of retroviral and transposon integration profiles. PLoS Genet 2014; 10: e1004250
46. Grabundzija I, Irgang M, Mates L, Belay E, Matrai J, Gogol-Doring A et al. Comparative analysis of transposable element vector systems in human cells. Mol Therapy 2010; 18: 1200-1209
47. Huang X, Guo H, Tammana S, Jung YC, Mellgren E, Bassi P et al. Gene transfer efficiency and genome-wide integration profiling of Sleeping Beauty, Tol2, and piggyBac transposons in human primary T cells. Mol Ther 2010; 18: 1803-1813
48. Maldarelli F, Wu X, Su L, Simonetti FR, Shao W, Hill S et al. HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science 2014; 345: 179-183
49. Voigt K, Gogol-Doring A, Miskey C, Chen W, Cathomen T, Izsvak Z et al. Retargeting sleeping beauty transposon insertions by engineered zinc finger DNA-binding domains. Mol Ther 2012; 20: 1852-1862
50. Ivics Z, Katzer A, Stuwe EE, Fiedler D, Knespel S, Izsvak Z. Targeted Sleeping Beauty transposition in human cells. Mol Ther 2007; 15: 1137-1144
51. Riddell SR, Sommermeyer D, Berger C, Liu LS, Balakrishnan A, Salter A et al. Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition. Cancer J 2014; 20: 141-144.